文献速递心脑血管急症消化、代谢与肾脏急症

茶苯海明与甲氧氯普胺治疗眩晕所致恶心的疗效比较:一项随机研究

Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study.
PubMed 文献 · Am J Emerg Med · 2020-12-10
一句话结论在急诊眩晕伴恶心患者中,静脉茶苯海明50 mg与甲氧氯普胺10 mg在30分钟时减轻眩晕和恶心方面疗效相似,不良反应无差异。

该前瞻性、双盲、随机对照研究纳入200例18–65岁因眩晕伴恶心或晕动症就诊急诊的患者,随机分为茶苯海明组(50 mg静脉输注15分钟)和甲氧氯普胺组(10 mg静脉输注15分钟)。主要终点为给药后30分钟眩晕VAS评分下降,两组30分钟眩晕VAS分别降至2.46±2.39和2.31±1.96,差异无统计学意义;恶心VAS变化、解救药物需求和不良反应(镇静、低血压)亦无显著差异。研究表明两种药物在急诊眩晕相关恶心治疗中疗效相当。

要点

  • 纳入18–65岁急诊眩晕伴恶心或晕动症患者,茶苯海明50 mg与甲氧氯普胺10 mg均静脉输注15分钟。
  • 30分钟眩晕VAS:茶苯海明组2.46±2.39 vs 甲氧氯普胺组2.31±1.96,组间无显著差异。
  • 30分钟恶心VAS:茶苯海明组2.27±2.24 vs 甲氧氯普胺组2.70±2.48,组间无显著差异。
  • 解救药物需求两组相似(p=0.94),镇静(p=0.56)和低血压(p=0.57)无显著差异。

适用人群与场景

  • 18至65岁成人,因眩晕伴恶心或晕动症就诊于急诊科。

诊断标准与关键阈值

  • 使用10 mm视觉模拟量表(VAS)评估眩晕和恶心,于0、15、30分钟进行。
  • 主要结局变量为给药后30分钟眩晕VAS评分的下降。

处置流程与药物剂量

  • 茶苯海明组:50 mg静脉输注15分钟。
  • 甲氧氯普胺组:10 mg静脉输注15分钟。
  • 解救药物需求两组相似(p=0.94),原文未提及具体解救药物名称和剂量。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性、双盲、随机对照试验;样本量200例(每组100例);单中心(急诊科)。
  • 基线眩晕VAS:茶苯海明组7.57±1.42,甲氧氯普胺组7.27±1.40(p=0.09)。
  • 30分钟眩晕VAS:茶苯海明组2.46±2.39,甲氧氯普胺组2.31±1.96,组间无显著差异。
  • 基线恶心VAS:茶苯海明组7.62±1.48,甲氧氯普胺组7.45±1.27(p=0.36);30分钟恶心VAS:茶苯海明组2.27±2.24,甲氧氯普胺组2.70±2.48,组间无显著差异。
  • 恶心VAS变化与眩晕VAS变化在30分钟时无显著差异(p=0.06,p=0.85)。
  • 解救药物需求两组相似(p=0.94)。
  • 不良反应:镇静(p=0.56)、低血压(p=0.57)无显著差异。

证据类型、等级与局限

  • 证据类型:前瞻性、双盲、随机对照试验。
  • 局限:单中心研究,样本量200例,仅纳入18–65岁成人,结果需多中心验证。

对床旁实践的改变

  • 对于急诊成人眩晕伴恶心患者,茶苯海明50 mg静脉输注15分钟或甲氧氯普胺10 mg静脉输注15分钟均可作为选择,两者在30分钟时减轻眩晕和恶心疗效相似。
  • 选择药物时需考虑患者个体情况,但原文未给出具体选择建议。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: This study aimed to compare the therapeutic efficacy of dimenhydrinate and metoclopramide in patients with nausea and vertigo.

METHODS: A prospective, double-blind, randomized clinical trial was performed on patients who presented to the emergency department (ED) with nausea and vertigo in the six month period between Nov 1st 2012 and May 1st 2013. Adult patients who were 18 to 65 years old presenting to the ED with nausea and vertigo or motion sickness were included in the study. A total of 200 patients were divided into 2 groups who were admitted to ED with complaints of vertigo accompanied by nausea. In the first group, 50 mg dimenhydrinate and 10 mg metoclopramide infusions were given intravenously for 15 min. The efficacy of treatment was measured by using a 10 mm Visual Analog Scale (VAS) performed at 0, 15 and the 30th minute. The primary outcome variable was a reduction in vertigo intensity documented on the VAS at the 30th minute after medication administration.

RESULTS: A total of 200 patients were included in the randomization (n=100 in both groups). The baseline vertigo VAS scores were 7.57±1.42 in the dimenhydrinate (DMT) group and 7.27±1.40 in the metoclopramide (MTP) group (p=0.09). In the 30th minute of treatment, the average vertigo VAS score was 2.46 ± 2.39 in the DMT group and 2.31±1.96 in the MTP group; no significant differences were detected between groups. The baseline nausea VAS scores were 7.62±1.48 in the DMT group and 7.45±1.27 in the MTP group (p=0.36). In the 30th minute of treatment the average vertigo VAS score decreased to 2.27±2.24 in the DMT group and 2.70±2.48 in the MTP group, no significant differences were detected between groups. No significant differences were detected between nausea VAS changes and vertigo VAS changes at 30th minutes of the treatment (p=0.06, p=0.85 respectively). Rescue medication need was similar in both treatment groups (p=0.94). No significant differences were detected about the side effects which are sedation (p=0.56) and hypotension (p=0.57).

CONCLUSIONS: In conclusion, this prospective, double-blind, randomized study showed that both DMT and MTP have similar efficacy in reducing nausea and vertigo symptoms in the ED.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Ercin D, Erdur B, Turkcuer I, et al. Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study. Am J Emerg Med. 2020. PMID: 33360021. doi:10.1016/j.ajem.2020.12.010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。